Medtronic releases new renal denervation results, closes trial enrollment

The Symplicity Spyral renal denervation system delivers energy to the nerves leading to the kidneys, which help regulate blood pressure. [Image courtesy of Medtronic]Medtronic (NYSE:MDT) today said its Symplicity Spyral renal denervation (RDN) system demonstrated durable, clinically significant blood pressure reductions through three years for patients on medication.

It’s the latest development out of Medtronic’s Spyral HTN-ON MED trial testing the company’s RDN catheter system, which delivers radiofrequency energy to overactive nerves near the kidneys that cause high blood pressure. Medtronic released the results in The Lancet and at the American College of Cardiology’s 71st Annual Scientific Session.

“For the first time, we now have randomized data that demonstrates that in a typical patient population — hypertension patients who are on anti-hypertensive medications and treated with RDN — we are seeing the continued, long-term blood pressure lowering effect,” Dr…

Read more
  • 0

Medtronic releases new renal denervation results, closes trial enrollment

The Symplicity Spyral renal denervation system delivers energy to the nerves leading to the kidneys, which help regulate blood pressure. [Image courtesy of Medtronic]

Medtronic (NYSE:MDT) today said its Symplicity Spyral renal denervation (RDN) system demonstrated durable, clinically significant blood pressure reductions through three years for patients on medication.

It’s the latest development out of Medtronic’s Spyral HTN-ON MED trial testing the company’s RDN catheter system, which delivers radiofrequency energy to overactive nerves near the kidneys that cause high blood pressure. Medtronic released the results in The Lancet and at the American College of Cardiology’s 71st Annual Scientific Session.

“For the first time, we now have randomized data that demonstrates that in a typical patient population — hypertension patients who are on anti-hypertensive medications and t…

Read more
  • 0

MedtronicTalks: Why Symplicity Spyral trials are complicated, but worth it

Medtronic’s campaign to secure FDA approval  – Symplicity Spyral – has been anything but simple.

But in this episode of the MedtronicTalks podcast, Jason Weidman, senior vice president and president of Coronary & Renal Denervation, explains why the company has refused to give up the fight to develop the renal denervation tool to lower hypertension.

Weidman explains why the company couldn’t share updated clinical data this fall as it hoped and he gives a new timeframe for the next milestone.

MedtronicTalks · Weidman walks the long road to get Symplicity Spiral ready to help patients with hypertension
Read more
  • 0

What is renal denervation? Medtronic Coronary and RDN President Jason Weidman explains

Jason Weidman is a Medtronic SVP and president of its coronary and renal denervation business. [Photo courtesy of Medtronic]

As Medtronic (NYSE:MDT) continues clinical trials of its Symplicity Spyral renal denervation (RDN) system for treating hypertension, the Fridley, Minnesota-based medical device maker now hopes to win FDA approval in 2023.

To better understand the technology behind what Medtronic leaders expect to become a multibillion-dollar business, Medical Design & Outsourcing spoke with Jason Weidman, Medtronic senior vice president and president of the coronary and renal denervation business, which is part of Medtronic’s cardiovascular portfolio. (We’ve edited this conversation for brevity and clarity.)

MDO: What’s the simplest way to explain renal denervation?

Weidman: The basic idea is that your kidneys are part of the body’s blood pressure control mechanis…

Read more
  • 0

Medtronic builds suspense for renal denervation study results

The Symplicity Spyral renal denervation system delivers energy to the nerves leading to the kidneys, which help regulate blood pressure. [Image courtesy of Medtronic]Medtronic’s clinical study of its Symplicity Spyral renal denervation system for hypertension is likely to go down to the wire for inclusion as a late-breaking clinical trial at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) conference.

The highly anticipated results will offer new insight into the Fridley, Minnesota-based medical device manufacturer’s quest to build a billion-dollar business treating hypertension. CEO Geoff Martha recently reported “good progress” in those efforts, saying the trial “represents the final piece of a large body of evidence that we intend to submit to the FDA for approval.”

Get the full story at our sister site, Medical Design & Outsourcing.

Read more
  • 0

Medtronic builds suspense for renal denervation study results

Medtronic’s Symplicity Spyral renal denervation system delivers energy to the nerves leading to the kidneys, which help regulate blood pressure. [Image courtesy of Medtronic]

Medtronic’s clinical study of its Symplicity Spyral renal denervation system for hypertension is likely to go down to the wire for inclusion as a late-breaking clinical trial at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) conference.

The highly anticipated results will offer new insight into the Fridley, Minnesota-based medical device manufacturer’s quest to build a billion-dollar business treating hypertension. CEO Geoff Martha recently reported “good progress” in those efforts, saying the trial “represents the final piece of a large body of evidence that we intend to submit to the FDA for approval.”

Medtronic (NYSE:MDT) said it still hopes to present results of its Spyral HTN-ON MED trial at the Cardiovascul…

Read more
  • 0